Summary
Pfizer Inc. (PFE) announced on December 20, 2018, a significant strategic move to combine its consumer healthcare business with GlaxoSmithKline plc (GSK) through a joint venture. Under the agreement, Pfizer will contribute its consumer healthcare assets and liabilities to a newly formed joint venture, receiving in return a 32% equity stake, while GSK will hold the remaining 68%. This transaction is a pivotal step for Pfizer in streamlining its business focus. The agreement has received unanimous board approval from both companies, but its consummation is contingent upon customary closing conditions, including GSK shareholder approval and necessary antitrust clearances. The deal also includes provisions for indemnification and termination rights, with a potential $900 million termination fee payable by GSK under specific circumstances.
Key Highlights
- 1Pfizer is entering a definitive agreement to combine its consumer healthcare business with GSK's.
- 2The transaction will form a joint venture where Pfizer will hold a 32% equity interest and GSK will hold 68%.
- 3The agreement involves the sale of Pfizer's worldwide consumer healthcare assets and liabilities to the joint venture.
- 4Both Pfizer's and GSK's boards of directors have unanimously approved the transaction.
- 5The closing of the deal is subject to conditions, including GSK shareholder approval and antitrust clearances.
- 6The agreement includes provisions for indemnification and potential termination fees, with GSK owing Pfizer $900 million if specific conditions related to shareholder approval are not met.
- 7Ancillary agreements, including a shareholders' agreement and transition services agreements, will be entered into at closing to govern the joint venture's operations.